Ikena Oncology and Inmagene Biopharmaceuticals announce agreement for merger
The transaction is expected to result in approximately $175 million to support further development of IMG-007
The transaction is expected to result in approximately $175 million to support further development of IMG-007
Extension of long-term collaboration includes construction of new customer-dedicated bioconjugation capacity in Visp (CH) and commercial antibody supply of a new ADC
TTP Group is a leading engineering firm specializing in biotech and pharmaceutical industry
CN201 is a next generation CD3xCD19 bispecific antibody that augments and diversifies Merck’s pipeline, with potential applications in B-cell malignancies and autoimmune diseases
Contepo offers a unique mechanism of action and has the potential to address increasing antibiotic resistance and gaps in the current antibiotic treatment landscape
Adds first-in-class investigational asset, NX-13, to AbbVie's pipeline with the potential to offer a novel approach to the treatment of ulcerative colitis (UC) and Crohn's disease (CD)
The acquisition is immediately accretive and creates a compelling, single-stop, multi-continent partner for biopharma companies
Wacker Biotech US, a wholly owned subsidiary of Wacker Chemie AG, specializes in the microbial production of pDNA
Wacker Biotech is a CDMO for the GMP-compliant production of active ingredients for the pharmaceutical industry
Subscribe To Our Newsletter & Stay Updated